17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Friesen WJ, Johnson B, Sierra J, Zhuo J, Vazirani P, Xue X, Tomizawa Y, Baiazitov R, Morrill C, Ren H, Babu S, Moon YC, Branstrom A, Mollin A, Hedrick J, ... ... Peltz SW, et al. The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential. Plos One. 13: e0206158. PMID 30359426 DOI: 10.1371/journal.pone.0206158  0.52
2018 Cao L, Weetall M, Trotta C, Cintron K, Ma J, Kim MJ, Furia B, Romfo C, Graci JD, Li W, Du J, Sheedy J, Hedrick J, Risher N, Yeh S, ... ... Peltz SW, et al. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties. Molecular Cancer Therapeutics. PMID 30352802 DOI: 10.1158/1535-7163.MCT-18-0863  0.52
2017 Friesen WJ, Trotta CR, Tomizawa Y, Zhuo J, Johnson B, Sierra J, Roy B, Weetall M, Hedrick J, Sheedy J, Takasugi J, Moon YC, Babu S, Baiazitov R, Leszyk JD, ... ... Peltz SW, et al. The nucleoside analog clitocine is a potent and efficacious readthrough agent. Rna (New York, N.Y.). PMID 28096517 DOI: 10.1261/rna.060236.116  0.52
2016 Weetall M, Davis T, Elfring G, Northcutt V, Cao L, Moon YC, Riebling P, Dali M, Hirawat S, Babiak J, Colacino J, Almstead N, Spiegel R, Peltz SW. Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation. Clinical Pharmacology in Drug Development. 5: 296-305. PMID 27310330 DOI: 10.1002/cpdd.240  0.4
2014 Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, Ling KK, Karp GM, Qi H, Woll MG, Chen G, Zhang N, Gabbeta V, Vazirani P, Bhattacharyya A, ... ... Peltz SW, et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science (New York, N.Y.). 345: 688-93. PMID 25104390 DOI: 10.1126/science.1250127  0.52
2014 Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, ... ... Peltz SW, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine. 2: 539-47. PMID 24836205 DOI: 10.1016/S2213-2600(14)70100-6  0.52
2013 Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. Annual Review of Medicine. 64: 407-25. PMID 23215857 DOI: 10.1146/annurev-med-120611-144851  0.52
2010 Wang B, Yang Z, Brisson BK, Feng H, Zhang Z, Welch EM, Peltz SW, Barton ER, Brown RH, Sweeney HL. Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. Journal of Applied Physiology (Bethesda, Md. : 1985). 109: 901-5. PMID 20558759 DOI: 10.1152/japplphysiol.01366.2009  0.52
2009 Peltz SW, Welch EM, Trotta CR, Davis T, Jacobson A. Targeting post-transcriptional control for drug discovery. Rna Biology. 6: 329-34. PMID 19574739  0.52
2009 Peltz SW, Welch EM, Jacobson A, Trotta CR, Naryshkin N, Sweeney HL, Bedwell DM. Nonsense suppression activity of PTC124 (ataluren). Proceedings of the National Academy of Sciences of the United States of America. 106: E64; author reply E6. PMID 19506240 DOI: 10.1073/pnas.0901936106  0.52
2008 Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proceedings of the National Academy of Sciences of the United States of America. 105: 2064-9. PMID 18272502 DOI: 10.1073/pnas.0711795105  0.52
2007 Bhattacharyya A, Trotta CR, Peltz SW. Mining the GEMS--a novel platform technology targeting post-transcriptional control mechanisms. Drug Discovery Today. 12: 553-60. PMID 17631250 DOI: 10.1016/j.drudis.2007.05.009  0.4
2007 Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, ... ... Peltz SW, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 447: 87-91. PMID 17450125 DOI: 10.1038/nature05756  0.52
2007 Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. Journal of Clinical Pharmacology. 47: 430-44. PMID 17389552 DOI: 10.1177/0091270006297140  0.52
2006 Trotta CR, Paushkin SV, Patel M, Li H, Peltz SW. Cleavage of pre-tRNAs by the splicing endonuclease requires a composite active site. Nature. 441: 375-7. PMID 16710424 DOI: 10.1038/nature04741  0.4
2006 Mehta A, Trotta CR, Peltz SW. Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells. Genes & Development. 20: 939-53. PMID 16598037 DOI: 10.1101/gad.1388706  0.4
2004 Paushkin SV, Patel M, Furia BS, Peltz SW, Trotta CR. Identification of a human endonuclease complex reveals a link between tRNA splicing and pre-mRNA 3' end formation. Cell. 117: 311-21. PMID 15109492  0.4
Show low-probability matches.